Journal
MOLECULAR BIOTECHNOLOGY
Volume 39, Issue 2, Pages 97-104Publisher
HUMANA PRESS INC
DOI: 10.1007/s12033-008-9046-7
Keywords
gene delivery; non-viral; transient protein expression; vector design; gene therapy; DNA vaccines; plasmid DNA; DNA structure; plasmid size; bacterial minimal vector; antibiotic resistance gene
Ask authors/readers for more resources
Although non-viral gene delivery is a very straightforward technology, there are currently no FDA-approved gene medicinal products available. Therefore, improving potency, safety, and efficiency of current plasmid DNA vectors will be a major task for the near future. This article will provide an overview on factors influencing production yield and quality as well as safety issues that emerge from the vector design itself. Special focus will be on generating bacterial pDNA vectors by circumventing the use of antibiotic resistance genes, to generate safer gene medicinal products as well as smaller, more efficient DNA vectors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available